公开(公告)号：HUT60598A

公开(公告)日：1992-10-28

申请号：HU9200537

申请日：1992-02-19

Applicant: BASF AG

Inventor： GRAMMENOS WASSILIOS ,  HARREUS ALBRECHT ,  SAUTER HUBERT ,  HELLENDAHL BEATE ,  DOETZER REINHARD ,  AMMERMANN EBERHARD ,  LORENZ GISELA

IPC: A01N37/50 ,  A01N43/54 ,  A01N43/58 ,  A01N43/76 ,  A01N43/836 ,  C07C69/65 ,  C07C69/653 ,  C07C69/734 ,  C07C69/738 ,  C07C251/48 ,  C07C251/50 ,  C07C251/52 ,  C07C251/54 ,  C07C251/56 ,  C07C251/58 ,  C07C251/60 ,  C07C251/86 ,  C07C255/15 ,  C07C255/57 ,  C07C255/58 ,  C07C255/62 ,  C07D213/77 ,  C07D239/42 ,  C07D241/20 ,  C07D263/32 ,  C07D333/28 ,  A01N43/40 ,  A01N43/74 ,  A01N43/82 ,  A01N43/60 ,  C07C251/32 ,  C07C255/66 ,  C07C249/16

Abstract: Iminoalkyl-phenylacrylic acid derivs. (I) ar new: R = H or 1-6C alkyl; R = H; 1-4C alkyl opt. substd. by halo; or opt. substd. aryl; Z ,Z = H; halo; CN; NO2;etc.;Y = O; NH; or NR ; and R = H; 1-4C alkoxycarbonyl-1-4C alkyl; or opt. substd. alkyl, cycloalkyl, etc.; or Y+R form a ring which is opt. substd. when Y = NH or NR ; R = 1-6C alkyl; X = CH-1-4C alkoxy or CH-1-4C alkylthio (also 1-4C alkylidene and 1-4C alkoxyimino in the description).

公开(公告)号：HU9200537D0

公开(公告)日：1992-05-28

申请号：HU9200537

申请日：1992-02-19

Applicant: BASF AG

Inventor： GRAMMENOS WASSILIOS ,  HARREUS ALBRECHT ,  SAUTER HUBERT ,  HELLENDAHL BEATE ,  DOETZER REINHARD ,  AMMERMANN EBERHARD ,  LORENZ GISELA

IPC: A01N37/50 ,  A01N43/54 ,  A01N43/58 ,  A01N43/76 ,  A01N43/836 ,  C07C69/65 ,  C07C69/653 ,  C07C69/734 ,  C07C69/738 ,  C07C251/48 ,  C07C251/50 ,  C07C251/52 ,  C07C251/54 ,  C07C251/56 ,  C07C251/58 ,  C07C251/60 ,  C07C251/86 ,  C07C255/15 ,  C07C255/57 ,  C07C255/58 ,  C07C255/62 ,  C07D213/77 ,  C07D239/42 ,  C07D241/20 ,  C07D263/32 ,  C07D333/28

Abstract: Iminoalkyl-phenylacrylic acid derivs. (I) ar new: R = H or 1-6C alkyl; R = H; 1-4C alkyl opt. substd. by halo; or opt. substd. aryl; Z ,Z = H; halo; CN; NO2;etc.;Y = O; NH; or NR ; and R = H; 1-4C alkoxycarbonyl-1-4C alkyl; or opt. substd. alkyl, cycloalkyl, etc.; or Y+R form a ring which is opt. substd. when Y = NH or NR ; R = 1-6C alkyl; X = CH-1-4C alkoxy or CH-1-4C alkylthio (also 1-4C alkylidene and 1-4C alkoxyimino in the description).

公开(公告)号：CA2195243C

公开(公告)日：2006-05-30

申请号：CA2195243

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  DRESCHER KARLA ,  TESCHENDORF HANS-JURGEN ,  WICKE KARSTEN ,  BIALOJAN SIEGFRIED ,  MUNSCHAUER RAINER ,  UNGER LILIANE

IPC: C07D249/08 ,  C07D403/12 ,  A61K31/41 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61P1/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D249/12 ,  C07D249/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14

Abstract: The present invention relate to triazole compounds of formula (I) in which R 1, R2 stand for H or different substituents, A stands for a bivalent group, B stands for a test of the formula (a), (b) or (c) and Ar stands for optionally substituted phenyl, pyridyl, pyrimidyl or triazinyl. The compounds of the invention have a high affinity for the dopamine-D3-receptor and are therefore usable for the treatment of disease responding to dopamine-D3-ligands.

公开(公告)号：AT234616T

公开(公告)日：2003-04-15

申请号：AT95926897

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MUELLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JUERGEN ,  WICKE KARSTEN

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12

Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.

公开(公告)号：NZ290388A

公开(公告)日：2001-04-27

申请号：NZ29038895

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MULLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JURGEN ,  WICKE CARSTEN

IPC: A61K31/33 ,  A61K31/415 ,  A61K31/44 ,  C07D233/84 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/496 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D213/56 ,  C07D213/64 ,  C07D213/65 ,  C07D213/70 ,  C07D213/73 ,  C07D213/79 ,  C07D213/81 ,  C07D233/90 ,  C07D307/79 ,  C07D333/24 ,  C07D333/28 ,  C07D333/38 ,  C07D471/18

Abstract: Use of a compound of the formula Het-A-B-Ar and the salts thereof with physiologically tolerated acids, in the manufacture of a medicament for treating disorders that respond to dopamine D3 receptor antagonists, wherein: A is a straight or branched alkylene group which contains at least one group which is selected from among O, S, NR4, CONR4, NR4 CO, COO, and OCO; B is a radical of formulae (I); Ar is a phenyl, pyridyl, pyrimidyl or triazinyl, where Ar may have one to four substituents selected from the group consisting of OR4, alkyl, alkenyl, alkynyl, halogen, CN, CO2R4, NO2, SO2R4, SO3R4, NR4R5, SO2NR4R5, SR4, CF3, CHF2, a 5- or a 6-membered carbocyclic, aromatic or non-aromatic ring and a 5- or a 6-membered heterocyclic, aromatic or non-aromatic ring having 1 to 3 hetero atoms which are selected from O, S and N, where the carbocyclic or the heterocyclic ring is unsubstituted or substituted by alkyl, halogen, O-alkyl, OH, NO2 or CF3, and where Ar may also be fused to a 5- or 6-membered carbocyclic, aromatic ring or to a 5- or 6-membered heterocyclic, aromatic or non-aromatic ring having 1 to 3 heteroatoms which are selected from O, S and N, where the carbocyclic or the heterocyclic ring is unsubstituted or substituted by -alkyl, halogen, O-alkyl, OH, NO2 or CF3; Het is a group of formulae (II); R1, R2 and R3 are, independently of one another, H, halogen, OR5, NR4R5, SR4, CF3, CN or alkyl which is unsubstituted or substituted by OH, O-alkyl or halogen; R4 is H or alkyl unsubstituted or substituted by OH, O-alkyl or halogen; R5 is the meaning indicated for R4 or is COR4 or CO2R4.

公开(公告)号：AU704839B2

公开(公告)日：1999-05-06

申请号：AU3111495

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MULLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JURGEN ,  WICKE CARSTEN

IPC: C07D233/84 ,  A61K31/33 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/496 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D213/56 ,  C07D213/64 ,  C07D213/65 ,  C07D213/70 ,  C07D213/73 ,  C07D213/79 ,  C07D213/81 ,  C07D233/90 ,  C07D307/79 ,  C07D333/24 ,  C07D333/28 ,  C07D333/38 ,  C07D471/18

Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

公开(公告)号：NZ290389A

公开(公告)日：1999-03-29

申请号：NZ29038995

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  MUNSCHAUER RAINER ,  BIALOJAN SIEGFRIED ,  UNGER LILIANE ,  TESCHENDORF HANS-JURGEN ,  WICKE KARSTEN ,  DRESCHER KARLA

IPC: C07D239/26 ,  A61K31/505 ,  A61K31/506 ,  A61P25/16 ,  A61P25/24 ,  A61P25/26 ,  C07D239/38 ,  C07D239/46 ,  C07D239/56 ,  C07D239/60 ,  C07D401/00 ,  C07D401/12 ,  C07D401/14

Abstract: The present invention relates to the use of pyrimidine compounds of the following formula:wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

公开(公告)号：NZ290387A

公开(公告)日：1999-02-25

申请号：NZ29038795

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  MUNSCHAUER RAINER ,  BIALOJAN SIEGFRIED ,  UNGER LILIANE ,  TESCHENDORF HANS-JURGEN ,  WICKE KARSTEN ,  DRESCHER KARLA

IPC: C07D249/08 ,  A61K31/41 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61P1/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D249/12 ,  C07D249/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14

Abstract: PCT No. PCT/EP95/02781 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02520 PCT Pub. Date Feb. 1, 1996The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

公开(公告)号：HUT77554A

公开(公告)日：1998-05-28

申请号：HU9700115

申请日：1995-07-14

Applicant: BASF AG

Inventor： BACH ALFRED ,  HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MUELLER BEATRICE ,  TESCHENDORF HANS-JUERGEN ,  UNGER LILIANE ,  WICKE KARSTEN

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12 ,  A61K31/495 ,  A61K31/505

Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.

公开(公告)号：BG101113A

公开(公告)日：1998-04-30

申请号：BG10111397

申请日：1997-01-06

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  MUNSCHAUER RAINER ,  BIALOJAN SIEGFRIED ,  UNGER LILIANE ,  TESCHENDORF HANS-JUERGEN ,  WICKE KARSTEN ,  DRESCHER KARLA

IPC: C07D249/08 ,  A61K31/41 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61P1/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D249/12 ,  C07D249/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14

Abstract: The invention relates to triazole compounds with the formulawhere R1 & R2 mean hydrogen or different substituents, A is atwo-valent group, B is residue with formula a, b or c and Ar in agiven case means substituted phenyl, pyridyl, pyrimidyl ortriazinyl. The compounds have higher affinity todopamine-D3-receptors and can be used for the treatment ofdiseases which react to dopamine-D3-ligands.13 claims